MedTrace Logo

Local Therapy for ER/PR-positive Oligometastatic Breast Cancer

NCT04698252 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2022-08-08

No results posted yet for this study

Summary

Randomized phase 2 trial to evaluate the efficacy of local therapy for oligometastasis from ER/PR-positive breast cancer. The study hypothesis is that local therapy in addition to systemic therapy improves progression-free survival in comparison with systemic therapy alone.

Conditions

Interventions

RADIATION

Radiotherapy

Radiation therapy for oligometastatic sites

PROCEDURE

Surgery

Surgery for oligometastatic sites

OTHER

Radiofrequency ablation

Radiofrequency ablation for oligometastatic sites

Sponsors & Collaborators

  • Instituto do Cancer do Estado de São Paulo

    lead OTHER

Principal Investigators

  • Renata C. Bonadio, MD · Instituto do Cancer do Estado de São Paulo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2024-04-01
Completion
2031-04-01

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04698252 on ClinicalTrials.gov